New hope for kids with lupus: belimumab shows promise in chinese trial
NCT ID NCT04908865
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether adding belimumab to standard treatment is safe and effective for Chinese children aged 5 to 17 with active lupus. 67 participants received belimumab plus their usual therapy. The main goal was to check for serious side effects and see if lupus disease activity decreased over 52 weeks. Results showed that many children had a significant reduction in disease activity, though some experienced infections or allergic reactions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belimumab
What this could lead to
If successful, this could provide a treatment option for children with lupus that helps control disease activity and reduce flares.
What could go wrong
This is a Phase 4 study in a specific population (Chinese children), so results may not apply to other groups. Side effects like infections and allergic reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Beijing, 100045, China
-
GSK Investigational Site
Changchun, 130021, China
-
GSK Investigational Site
Changsha, 410007, China
-
GSK Investigational Site
Chongqing, 400014, China
-
GSK Investigational Site
Hangzhou, 310052, China
-
GSK Investigational Site
Nanjing, 210011, China
-
GSK Investigational Site
Shanghai, 361006, China
-
GSK Investigational Site
Suzhou, 215007, China
-
GSK Investigational Site
Xi'an, 710054, China